• Regulatory NewsRegulatory News

    FDA sets deadline for study data technical rejection criteria

    The US Food and Drug Administration (FDA) has set a deadline for when it will begin refusing to file or to receive electronic submissions that fail to meet the agency’s established electronic common technical document (eCTD) validation criteria.   Beginning 15 September 2021, FDA says it will “reject submissions that contain any high validation errors included in the [technical rejection criteria] TRC.” The new effective date for the technical rejection criteria was an...
  • Regulatory NewsRegulatory News

    FDA Drafts Guidance on Enhancing Diversity in Clinical Trial Populations

    The US Food and Drug Administration (FDA) on Thursday issued a draft guidance aimed at increasing diversity in clinical trial populations as part of its efforts to encourage drugmakers to enroll populations that more closely reflect the populations that will take the drugs in the real world.   “This guidance recommends approaches that sponsors of clinical trials to support a new drug application [NDA] or a biologics license application [BLA] can take to broaden eligibi...
  • Regulatory NewsRegulatory News

    FDA Finalizes Guidance on Targeted Therapies in Rare Genetic Subsets

    The US Food and Drug Administration (FDA) on Monday finalized guidance on developing targeted therapies in rare molecular subsets of diseases.   The 9-page guidance finalizes a draft version released in December 2017 and has been updated to incorporate comments submitted to the public docket and includes minor edits to improve clarity.   “By providing clarity on the regulatory and scientific frameworks for product developers, safe and effective targeted treatment...
  • Regulatory NewsRegulatory News

    Antimicrobial Susceptibility: FDA Launches Test Website, Issues Guidance

    The US Food and Drug Administration (FDA) on Wednesday launched a new website aimed at improving access to information that can help healthcare professionals determine which drugs are most likely to work to treat bacterial or fungal infections. The website is part of an effort mandated by the 21st Century Cures Act to combat rising antimicrobial resistance by providing a central, easily accessible and up-to-date repository for antimicrobial susceptibility interpretive ...
  • Regulatory NewsRegulatory News

    FDA Offers New ICH Guidance on Organizing a CTD

    The US Food and Drug Administration (FDA) this week released a guidance that is part of a series from the International Council of Harmonisation (ICH) on the format for preparing the Common Technical Document (CTD) for applications submitted to FDA. "A common format for the technical documentation will significantly reduce the time and resources needed to compile applications for registration of human pharmaceuticals and will ease the preparation of electronic subm...
  • Regulatory NewsRegulatory News

    Health Canada to go eCTD-only for Drug Applications

    Beginning on 1 January 2018, Health Canada will only accept submissions for certain regulatory procedures in electronic common technical document (eCTD) format. As of that date, Health Canada says that sponsors must use eCTD format for all new drug submissions (NDS) and abbreviated new drug submissions (ANDS), as well as supplements to both submission types. The agency also notes that sponsors can request an exemption from the requirement for individual products, but sa...
  • Regulatory NewsRegulatory News

    FDA Delays eCTD Requirements for Master Files

    The US Food and Drug Administration (FDA) is giving drugmakers an additional year before requiring master files to be submitted in electronic common technical document (eCTD) format. In a revised guidance released Friday, FDA says it is delaying the requirement for drug master files (DMF) and biological product files (BPF) to be submitted in eCTD format until 5 May 2018. Other documents, such as new drug applications (NDAs), abbreviated new drug applications (ANDAs) and...
  • Feature ArticlesFeature Articles

    Establishing a Joint Venture Pharmaceutical Manufacturing Entity in Japan

    This article focuses on key regulatory activities to establish a Joint Venture (JV) for pharmaceutical manufacturing and sales in Japan. The author describes foundation building, marketing authorization holder responsibilities, new drug applications, clinical trial sponsorship, adverse events reporting and brand name registrations as well as requirements for data archiving and post-marketing regulatory activities. Introduction With the support of the Japanese Ministry...
  • Regulatory NewsRegulatory News

    May Deadline for FDA's eCTD Transition Approaches

    Beginning 5 May, pharmaceutical, biologic and generic manufacturers will have to submit to the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) all New Drug Applications (NDAs), Biologics License Application (BLAs) and Abbreviated New Drug Applications (ANDAs) using the electronic Common Technical Document (eCTD). Drug Master Files (DMFs), Biological Product Files (BPFs)...
  • Feature ArticlesFeature Articles

    Strategies for Smarter Compliance in a Technology-Driven FDA Environment

    The article provides an overview of the significance of technology in the regulatory compliance process and offers strategies for smarter compliance. Introduction Come May 2017, the US Food and Drug Administration (FDA) will no longer accept submissions of drug applications that do not follow the electronic Common Technical Document (eCTD) format. This signifies further movement toward the use of technology in regulatory approvals and a key milestone in the modernizat...
  • Regulatory NewsRegulatory News

    FDA, NIH Unveil Initial Framework for Biomarker Qualification

    Officials from the US Food and Drug Administration (FDA), the Foundation for the National Institutes of Health (NIH) and other stakeholders, including experts from Genentech, Merck, Pfizer and Takeda, have released a framework for proposed evidentiary criteria to support the regulatory acceptance of biomarker use in drug development programs. The framework, released 6 December, is expected to help support FDA in the development of relevant guidance(s) for evidentiary cr...
  • Feature ArticlesFeature Articles

    China Food and Drug Administration Issues New Requirements for Clinical Trial Applications and New Drug Applications

    This article discusses the growth of China's pharmaceutical market, background of the global use and acceptance of the Common Technical Document (CTD), outlines the China Food and Drug Administration (CDFA) requirements for Clinical Trial Application (CTA) approval and New Drug Application (NDA) registration as critical steps in addressing drug quality, patient safety and shortening the time for access to new drugs. Introduction Earlier this year, the China Food and D...